Between billion-dollar IPOs and big-name exclusive partnerships, it's a good time to be a giant in the CRO world. However, all the recent consolidation has made it harder for mid-size outfits to compete, as medium-capped players lack the capacity to challenge heavyweights and don't offer the kind of niche services that keep small CROs afloat.
CMO UPM Pharmaceuticals is buying a 500,000-square-foot plant from Pfizer for an undisclosed sum, a huge boost to its capacity that comes paired with a big-name new client.
Satori Pharmaceuticals has closed its doors after running into safety problems in preclinical research of its lead program for Alzheimer's disease, FierceBiotech has learned.
UPM's top leadership is familiar with the Bristol, TN, facility; CEO John Gregory started King Pharma back in 1994.
The drugmaker had some success finding buyers for its excess capacity and struck another deal to sell a plant in Tennessee. This time it goes to family, so to speak.
In an effort to widen its search for new small-molecule drug candidates, Pfizer is extending its biologics partnership with the University of California, building on the company's already robust Centers for Therapeutic Innovation program.
As Bloomberg reports, Germany's Der Spiegel has ferreted more details about drug research in Soviet-era East Germany, where pharma groups tied to some of the biggest names in the industry reportedly benefited from cheap clinical trials before the fall of the Berlin Wall.
Reuters has looked inside the Pfizer lab tasked with developing a vaccine for the drug-resistant superbug MRSA.
Pfizer is cutting the apron strings at Zoetis. Just months after its highly successful IPO, in which Pfizer sold off a 20% stake, the animal health business is set to become fully independent. Pfizer is offering a stock swap to its shareholders, who can exchange $100 in Pfizer shares for roughly $107 worth of Zoetis stock.
So, do drug companies really spend more money on marketing than on R&D? In the Pipeline takes a look at that contention, and the cold hard facts are these: Probably not. But it's hard to tell for sure.